Want to see ANRO full AI Analyst Report?
ANRO Stock Chart & Stats
$35.13
$1.09(4.07%)
At close: 4:00 PM EDT
$35.13
$1.09(4.07%)
Day’s Range― - ―
52-Week Range$5.71 - $37.48
Previous Close$27.8
Volume499.76K
Average Volume (3M)627.24K
Market Cap
$887.66M
Enterprise Value$909.40M
Total Cash (Recent Filing)$243.73M
Total Debt (Recent Filing)$7.05M
Price to Earnings (P/E)―
Beta1.89
Next Earnings
Mar 24, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.48
Shares Outstanding39,242,104
10 Day Avg. Volume710,525
30 Day Avg. Volume627,240
Financial Highlights & Ratios
PEG Ratio0.66
Price to Book (P/B)3.40
Price to Sales (P/S)0.00
P/FCF Ratio-9.92
Enterprise Value/Market Cap1.02
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.94K
Enterprise Value/Ebitda-11.19
Forecast
1Y Price Target
$44.00Price Target Upside25.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-2.78
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Growing Asset BaseVery low leverage gives Alto greater financial flexibility while it funds clinical development, reducing the immediate burden of debt service. Positive equity and a larger asset base provide a stronger platform for pursuing pipeline milestones than a highly leveraged balance sheet would.
Funded Expansion Of Late-stage ALTO-207 TrialsThe capital raise materially strengthens Alto’s ability to advance ALTO-207 through expanded Phase 3 development, including a monotherapy trial in treatment-resistant depression. Greater liquidity can support sustained execution and reduce near-term disruption from funding needs.
Biomarker-driven Precision Medicine ModelA biomarker-driven development strategy can help focus trials on patient groups with a higher likelihood of response, potentially improving clinical decision-making and development efficiency. This approach provides a differentiated framework for advancing therapies in complex neuropsychiatric disorders.
Bears Say
No Commercial Revenue And Widening LossesAlto has not yet demonstrated commercial scale, leaving its financial profile dependent on future clinical and regulatory success. Widening losses without offsetting revenue increase the resources required to reach profitability and make operating performance vulnerable to further cost escalation.
Persistent And Increasing Cash BurnSustained negative operating and free cash flow means Alto is funding its operations through external capital rather than internally generated cash. Continued development spending could require additional financing over time, increasing dilution or limiting flexibility if capital markets become less supportive.
Capital Base Is Being ConsumedNegative return on equity indicates that the company’s substantial equity base is currently supporting losses rather than generating returns. Unless clinical progress eventually produces commercial revenue, continued consumption of capital can weaken long-term financing efficiency and shareholder value creation.
Alto Neuroscience, Inc. News
ANRO FAQ
What was Alto Neuroscience, Inc.’s price range in the past 12 months?
Alto Neuroscience, Inc. lowest stock price was $5.71 and its highest was $37.48 in the past 12 months.
What is Alto Neuroscience, Inc.’s market cap?
Alto Neuroscience, Inc.’s market cap is $887.66M.
When is Alto Neuroscience, Inc.’s upcoming earnings report date?
Alto Neuroscience, Inc.’s upcoming earnings report date is Mar 24, 2027 which is in 157 days.
How were Alto Neuroscience, Inc.’s earnings last quarter?
Alto Neuroscience, Inc. released its earnings results on Aug 12, 2026. The company reported -$0.65 earnings per share for the quarter, beating the consensus estimate of -$0.735 by $0.085.
Is Alto Neuroscience, Inc. overvalued?
According to Wall Street analysts Alto Neuroscience, Inc.’s price is currently Undervalued.
Does Alto Neuroscience, Inc. pay dividends?
Alto Neuroscience, Inc. does not currently pay dividends.
What is Alto Neuroscience, Inc.’s EPS estimate?
Alto Neuroscience, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alto Neuroscience, Inc. have?
Alto Neuroscience, Inc. has 39,242,104 shares outstanding.
What happened to Alto Neuroscience, Inc.’s price movement after its last earnings report?
Alto Neuroscience, Inc. reported an EPS of -$0.65 in its last earnings report, beating expectations of -$0.735. Following the earnings report the stock price went up 10.692%.
Which hedge fund is a major shareholder of Alto Neuroscience, Inc.?
Currently, no hedge funds are holding shares in ANRO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alto Neuroscience, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$44.00 (25.25% Upside)
$44.00 (25.25% Upside)
Blogger Sentiment
Bullish
ANRO Sentiment 80%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 399.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
273.12%
12-Months-Change
Fundamentals
Return on Equity
-46.46%
Trailing 12-Months
Asset Growth
60.93%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Alto Neuroscience, Inc.
Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is ALTO-300, a small molecule designed to function as both a melatonergic agonist and serotonergic antagonist, exhibiting antidepressant properties for MDD patients. For addressing the cognitive impairments linked with schizophrenia, Alto Neuroscience is advancing ALTO-101, an innovative small molecule phosphodiesterase 4 inhibitor. The company's therapeutic candidates further extend to ALTO-203, a pioneering small-molecule histamine H3 receptor inverse agonist intended for MDD patients experiencing heightened anhedonia, and ALTO-202, an orally available antagonist of the GluN2B subunit of the NMDA receptor, also under investigation for MDD. Beyond these individual drug candidates, the firm is engaged in developing novel drug combinations that demonstrate synergistic pharmacodynamic effects. Crucially, Alto Neuroscience leverages an advanced AI-enabled biomarker platform that synthesizes data concerning patients' brain activity and behavioral patterns. This platform's purpose is to accurately identify which individuals are most likely to respond positively to its cutting-edge product candidates. Alto Neuroscience, Inc., established in 2019, maintains its headquarters in Los Altos, California.
ANRO Stock 12 Month Forecast
Average Price Target
$44.00
▲(25.25% Upside)
Technical Analysis
Ownership Overview
4.17% Insiders
5.68% Mutual Funds
47.80% Other Institutional Investors
30.08% Public Companies and
Individual Investors